Evaluation of the UroVysion™ Test in Predicting Recurrence and/or Progression of Disease in Patients Receiving initial BCG for Primary High Grade TaT1 and CIS Urothelial Carcinoma of the Bladder

Yair Lotan*, UT Southwestern, Edward Messing, University of Rochester, Brant Inman, Duke, Siamak Daneshmand, USC, Wassim Kassouf, McGill University, Daniel Canter, Oschner, Tony Marble, Abbott Molecular Inc., Ajith M. Joseph., Abbott Molecular Inc., Stephen A. Boorjian, Mayo Clinic

Introduction

- •Patients diagnosed with high grade non-muscle invasive bladder cancer (NMIBC) and treated with BCG remain at risk for recurrence and progression of disease.
- •The UroVysion FISH assay (UroVysion) has been reported to predict response to BCG therapy.
- •Herein, we validated the association of UroVysion results with BCG-naïve patients at risk of subsequent disease recurrence/progression.

Materials and Methods

- •We performed a multi-center prospective study that enrolled patients with primary high grade Ta-T1 tumors, CIS or recurrent NMIBC who initiated BCG therapy.
- •UroVysion testing was performed on urine specimens collected prior to the first instillation of BCG therapy, at time of the 6th instillation, and at 3-month surveillance.
- •Clinicians were blinded to the UroVysion results for specimens collected pre-BCG and at the 6th instillation of BCG therapy
- •Patients were monitored for disease recurrence by cystoscopy following standard of care intervals.
- •Follow up data were collected at time of recurrence or progression and/or at 3 months, 6 months, and 9 months.

Results

- •The study included 151 patients (80% men) with stages of Ta (42%), T1 (25.8%), CIS alone (17.9%), Ta+CIS (2%), and T1+CIS (7.3%).
- •At baseline, 43.9% (65/148) were UroVysion positive.
- •There were 46 events, including 36 recurrences and 10 progressions.
 •KM survival curves demonstrate significant reduced event free survival for UroVysion positive tests at baseline, 6-week and 3 months (Figure).
- •Patients with a positive UroVysion test at baseline prior to BCG or at 6 week instillation were more likely to experience recurrence or progression at 6 months and 9 months but differences at 3 months were not statistically significant.


Patient Characteristics

Attribute	Classification	Total	FISH Positive @ Baseline	FISH Negative @ Baseline	Chi Square	p-Value
	Total	148 (116 + 32)	65/148 (43.9%)	83/148 (56.1%)	4.378	0.0364
	Uninformative	3				
	Range	27 - 93				
٨٥٥	Mean	70.1				
Age	Median	71				
	Std. Deviation	10.83				
	Male (2 uninform)	121/151 (80.1%)	50/121 (41.3%)	69/121 (57.0%)	5.969	0.0146
Gender	Female (1 uninform)	30/151 (19.9%)	15/30 (50.0%)	14/30 (46.7%)	0.067	0.7961
	Uninformative	3				
Stage	CIS (2 uninform)	27/151 (17.9%)	18/25 (72.0%)	7/25 (28.0%)	9.680	0.0019
	Ta (1 uninform)	64/151 (42.4%)	17/63 (27.0%)	46/63 (73.0%)	26.698	<0.0001
	T1 (with Ta/T1)	39/151 (25.8%)	19/39 (48.7%)	20/39 (51.3%)	0.051	0.8208
	CIS/Ta Dual Dx	3/151 (2.0%)	1/3 (33.3%)	2/3 (67.7%)	0.667	0.4142
	CIS/T1 Dual Dx	11/151 (7.3%)	8/11 (72.7%)	3/11 (27.3%)	4.545	0.0330
	Unknown (1) / Unspecified (6)	7/151 (4.6%)	2/7 (28.6%)	5/7 (71.4%)	2.571	0.1088
	Uninformative	3				
Grade	High (3 uninform)	141/151 (93.4%)	64/148 (43.2%)	74/148 (50%)	1.419	0.2336
	Low	7/151 (4.6%)	1/148 (0.68%)	6/148 (4.1%)	7.143	0.0075
	Unspecified	3/151 (2.0%)	0/148 (0.0%)	3/148 (2.0%)	6	0.0143
	Uninformative	3				

All 7 Sites Combined (N=148)	3 Months	6 Months	9 Months
Recurrence Rate	21/148	32/148	36/148
	(14.2%)	(21.6%)	(24.3%)
Progression Rate	5/148 (3.4%)	9/148 (6.1%)	10/148 (6.8%)
Total Events	26/148	41/148	46/148
	(17.6%)	(27.7%)	(31.1%)


FISH at Baseline (Prior to Initial BCG)

			Combined Events at 3 Months	Combined Events at 6 Months	Combined Events at 9 Months	p value (FISH+ vs FISH neg) @ 3 Months	p value (FISH+ vs FISH neg) @ 6 Months	p value (FISH+ vs FISH neg) @ 9 Months
FISH +	65		15/65 (23.1%)	28/65 (43.1%)	29/65 (44.6%)	0.1101	0.000	0.0016
FISH -		83	11/83 (13.3%)	13/83 (15.7%)	17/83 (20.5%)	0.1191	0.0002	0.0016




FISH at time of the 6th instillation

			Combined Events at 3 Months	Combined Events at 6 Months	Combined Events at 9 Months	p value (FISH+ vs FISH neg) @ 3 Months	p value (FISH+ vs FISH neg) @ 6 Months	p value (FISH+ vs FISH neg) @ 9 Months
FISH +	41		10/41 (24.4%)	18/41 (43.9%)	18/41 (43.9%)	0.1839	0.0035	0.0240
FISH -		88	13/88 (14.8%)	17/88 (19.3%)	21/88 (23.9%)			0.0210



FISH at 3 month Surveillance

			Combined Events at 3 Months	Combined Events at 6 Months	Combined Events at 9 Months	p value (FISH+ vs FISH neg) @ 3 Months	Ο,	p value (FISH+ vs FISH neg) @ 9 Months	
FISH +	35		10/35 (28.6%)	17/35 (48.6%)	18/35 (51.4%)	0.0393	0.0003		
FISH -		79	10/79 (12.7%)	13/79 (16.5%)	17/79 (21.5%)			0.0014	



Conclusions

- •Approximately one-third of patients who initiate BCG have recurrence or progression events within 9 months of diagnosis.
- •A positive UroVysion assay at baseline and at the conclusion of BCG therapy was associated with a significantly increased likelihood of experiencing such an event at 6 and 9 months.
- •These data may be utilized for guiding management as well as clinical trial enrollment.